Take Advantage of the Dip and Buy These 4 Beaten-Down Healthcare Stocks

NYSE: WST | West Pharmaceutical Services Inc. News, Ratings, and Charts

WST – The healthcare industry is expected to achieve solid growth with rising investments in the sector and soaring demand from an aging population. Therefore, we think it could be wise to bet on beaten-down healthcare stocks West Pharmaceutical (WST), Bio-Rad Laboratories (BIO), Quest Diagnostics (DGX), and Masimo Corporation (MASI), which possess solid rebound potential. Read on.

The healthcare industry is still reeling under an acute scarcity of skilled labor and other logistical disruptions. However, demand for healthcare services continues to grow consistently due to rising chronic diseases and an aging population.

With increased health awareness thanks to the COVID-19 pandemic, demand for advanced diagnostics, treatment, and research is soaring. And investors’ interest in this space is evident in the iShares U.S. Healthcare Providers ETF’s (IHF) 4.1% returns in the past six months versus the SPDR S&P 500 ETF Trust’s (SPY) 0.1% decline.

So, it could be wise to bet on beaten-down stocks West Pharmaceutical Services, Inc. (WST), Bio-Rad Laboratories, Inc. (BIO), Quest Diagnostics Incorporated (DGX), and Masimo Corporation (MASI), which we think hold solid upside potential.

Click here to checkout our Healthcare Sector Report for 2022

West Pharmaceutical Services, Inc. (WST)

WST in Exton, Pa., designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company has two segments, Proprietary Products and Contract-Manufactured Products. 

On Jan. 25, 2022, WST announced an exclusive supply and technology agreement with Corning Incorporated (GLW). Eric M. Green, President, and CEO, WST, said, “West and Corning have developed this exceptional collaboration to offer leading elastomer-glass system solutions for the containment and delivery of injectable medicines. At West, we value the state-of-the-art products offered by Corning and are excited to build together the next generation of integrated packaging and delivery innovations.”

WST’s net sales increased 28.9% year-over-year to $706.50 million for the third quarter, ended Sept. 30, 2021. Its operating profit came in at $181.40 million, up 82.9% year-over-year. The company’s adjusted net income increased 79.8% year-over-year to $156.80 million, while its adjusted EPS came in at $2.06, up 79.1% year-over-year.

Analysts expect WST’s revenue to increase 8.8% to $3.07 billion in 2022. Its EPS is estimated to increase 27.6% per annum for the next five years. In addition, it has surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past five trading days, the stock has declined 6.5% in price to close yesterday’s session at $379.32.

WST’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which indicates a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.

WST has a B grade for Growth, Quality, and Sentiment. In the Medical – Devices & Equipment industry, it is ranked #27 of 166 stocks. Click here to see the additional POWR Ratings for Value, Momentum, and Stability for WST.

Bio-Rad Laboratories, Inc. (BIO)

BIO manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. BIO is headquartered in Hercules, Calif.

BIO’s total assets came in at $17.78 billion for the period ended Dec. 31, 2021, compared to $12.97 billion for the period ended Dec. 31, 2020. Its short-term investments were $404.69 million, compared to $334.47 million for the same period in the prior year. Also, its other investments came in at $14.39 billion, compared to $9.56 billion in the prior year.

For its fiscal 2023, BIO’s revenue is expected to grow 4% year-over-year to $3.02 billion. Its EPS is estimated to increase 17.8% per annum for the next five years. In addition, it surpassed the consensus EPS estimates in each of the trailing four quarters.

Over the past month, the stock has declined 2.5% in price to close yesterday’s trading session at $612.69.

According to our POWR Ratings, BIO has an A grade for Sentiment. It is ranked #14 of 56 stocks in the Medical – Diagnostics/Research industry. Click here to see additional POWR Ratings for BIO (Growth, Value, Momentum, Stability, and Quality).

Quest Diagnostics Incorporated (DGX)

DGX in Madison, N.J. provides diagnostic testing, information, and services in the USA and internationally. It also develops and delivers diagnostic information services, like routine testing, non-routine and advanced clinical testing, anatomic pathology testing & other diagnostic information services.

On Feb. 3, 2022, Steve Rusckowski, Chairman, CEO, and President, said, “Quest is well-positioned in 2022 to deliver on our commitments. Our guidance for 2022 reflects lower demand for COVID-19 testing services; growth in the base business; and the impact of the previously announced one-year delay of PAMA cuts, partially offset by investments to accelerate growth.”

DGX’s base business revenues increased 9.3% year-over-year to $2.02 billion for its fiscal fourth quarter, ended Dec. 31, 2021. Its goodwill came in at $7.09 billion for the period ended Dec. 31, 2021, compared to $6.87 billion for the period ended Dec. 31, 2020. Furthermore, its total current liabilities came in at $1.75 billion, compared to $1.78 billion, for the same period in the prior year.

DGX surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has declined 7.4% in price to close the last trading session at $131.72.

DGX has a B grade for Value and Quality in our POWR Ratings system. It is ranked #10 of 56 stocks in the Medical – Diagnostics/Research industry. Click here to see the additional POWR Ratings for DGX (Momentum, Growth, Sentiment, and Stability).

Masimo Corporation (MASI)

An Irvine, Calif.-based global medical technology company, MASI develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. It aims to improve patient outcomes while reducing the cost of care simultaneously.

On Feb. 15, 2022, Joe Kiani, Chairman and CEO, MASI, said, “While 2021 was a very challenging year in global healthcare and for millions of patients, we were able to help ease the burden on hospitals and caregivers by providing them with our breakthrough technologies. Our team truly demonstrated our commitment to our mission and guiding principles by putting our customers and patients’ priorities first.”

MASI’s product revenue increased 11% year-over-year to $327.58 million for the fourth quarter, ended Jan. 1, 2022. Its non-GAAP net income came in at $70.06 million, up 22.3% year-over-year, while its non-GAAP EPS was $1.21, up 23.5% year-over-year.

Analysts expect MASI’s revenue to increase 9.4% to $1.36 billion in 2022. Its EPS is expected to increase 13.4% to $4.91 in 2023. In addition, it has surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has retreated 38.1% in price to close yesterday’s trading session at $144.20.

Under POWR Ratings, MASI has been accorded a “B” rating for Quality. Within the Medical – Devices & Equipment industry, it is ranked #45 of 166 stocks. Click here to see the additional POWR Ratings for Value, Sentiment, Momentum, Growth, and Stability for MASI.

Click here to checkout our Healthcare Sector Report for 2022


WST shares rose $0.18 (+0.05%) in premarket trading Thursday. Year-to-date, WST has declined -19.08%, versus a -5.97% rise in the benchmark S&P 500 index during the same period.


About the Author: Riddhima Chakraborty


Riddhima is a financial journalist with a passion for analyzing financial instruments. With a master's degree in economics, she helps investors make informed investment decisions through her insightful commentaries. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
WSTGet RatingGet RatingGet Rating
BIOGet RatingGet RatingGet Rating
DGXGet RatingGet RatingGet Rating
MASIGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Recession or Not Recession…That Is the Question

Every investor appreciates that recessions and bear markets go hand in hand. But the definition of a recession often seems more difficult to pin down. So are we in a recession? And if not, then does that mean that disaster has been averted or that the pain train is still rolling towards investors? This is an important debate because it helps us appreciate what lies ahead for the stock market (SPY). We will tackle this vital topic in this week's commentary. Read on below...

:  |  News, Ratings, and Charts

3 Cybersecurity Stocks to Buy on the Pullback

Tech stocks are rallying. Within the sector, cybersecurity stocks offer the best combination of growth and value especially as the sector's importance grows everyday. Read on to find out why investors should consider buying top cybersecurity stocks like Fortinet (FTNT), Qualys (QLYS), and OneSpan (OSPN).

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

:  |  News, Ratings, and Charts

Is Costco Stock Still a Buy Amid Retail Troubles?

Retail companies have faced significant headwinds this year due to sky-high inflation and supply chain disruptions. However, Costco Wholesale's (COST) strong revenue performance and consistent margins have helped the stock to remain resilient amid retail troubles. So is this stock worth adding to your portfolio now? Let’s find out…

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

Read More Stories

More West Pharmaceutical Services Inc. (WST) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All WST News